Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Reducing harm in the treatment of multidrug-resistant tuberculosis

When describing the profound hearing loss she suffered as a result of her treatment for multidrug-resistant tuberculosis, the noted advocate Nandita Venkatesan said: “My world fell silent around me. I am in front of people, but I am not here.”1 In the context of India’s National Tuberculosis Programme, she seems to be right: 8 years after she was clinically diagnosed, first with abdominal tuberculosis and then multidrug-resistant tuberculosis, Venkatesan was declared to be a treatment success. This outcome is a rarity in multidrug-resistant tuberculosis, for which global success rates are roughly 50%.